Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05670730 · ClinicalTrials.gov registry record · Phase 1
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
A Phase 1 study of Duchenne Muscular Dystrophy and Exon 44, sponsored by Avidity Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 10
- Study locations
NCT05670730 is a Phase 1 study of Duchenne Muscular Dystrophy and Exon 44 that has completed, run by Avidity Biosciences. The registered enrollment target is 70 participants, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT05670730, a Phase 1 study of Duchenne Muscular Dystrophy and Exon 44, has completed, sponsored by Avidity Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 10
- Study locations
Study Summary
AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping. Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers. Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AOC 1044
Study Locations (10)
California
- UCSD - La Jolla
- Stanford University - Palo Alto
Arkansas
- Arkansas Children's - Little Rock
Georgia
- Rare Disease Research - Atlanta - Atlanta
Iowa
- University of Iowa - Iowa City
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Minnesota
- Gillette Children's - Saint Paul
North Carolina
- Rare Disease Research NC - Hillsborough
Ohio
- Abigail Research Institute at Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2024-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05670730
The ClinicalTrials.gov registry entry for NCT05670730 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (83% lower). The listed sponsor is Avidity Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05670730 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, Arkansas, Georgia.
Frequently Asked Questions
What is clinical trial NCT05670730 about?
NCT05670730 is a clinical study titled "Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping". AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping. Part A is a single dose ...
What is the current status of trial NCT05670730?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2022-11-09. Estimated completion is 2024-11-25.
What conditions does trial NCT05670730 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, Exon 44.
What interventions are being tested in trial NCT05670730?
The interventions under investigation include: Placebo (DRUG), AOC 1044 (DRUG).
Who is sponsoring clinical trial NCT05670730?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05670730 being conducted?
This trial has 10 study locations across Arkansas, California, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
RECRUITING · Phase 1
-
NS-050/NCNP-03 in Boys With DMD (Meteor50)
RECRUITING · Phase 1
-
Trial of Cell Based Therapy for DMD
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 1
-
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.